Saruparib in Combination With… · NCT07711002

The registry lists NCT07711002 as not yet recruiting, last updated 2026-07-17. Enrolment is 1330 planned participants, an estimate. Interventions: Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone. Primary measures include Radiographic progression-free survival (rPFS). No results are posted in the registry; this does not exclude separate publications.

Setting

A Randomized, Double-Blind, Placebo-Controlled, 2-Cohort, Phase III Study of Saruparib Combined With Physician's Choice of Androgen Receptor Pathway Inhibitor in Patients With Metastatic Hormone-Sensitive Prostate Cancer, Previously Treated With Docetaxel or PSMA-directed 177Lutetium-Containing Therapy Without Disease Progression, and With Prostate-Specific Antigen ≥ 0.2 ng/mL: EvoPAR-Prostate05

Phase

Phase 3

Sponsor

AstraZeneca

Registry

NCT07711002

Started

2026-10-01 (estimated)

Enrolled

Connected

3

cancers

Prostate cancer

targets

PARP

drugs

Phase 3small molecule

Saruparib

Evidence strength30/100 · Emerging

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 3+30
No structured primary endpoint0
Result: planned0
No independent replication recorded0

Formula disclosed on the evidence page.

Follow this page

Follow by feed

Improve the information

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an edit

Cancers

Prostate cancer

Targets

PARP

Products

Saruparib

Sourced, not expert-reviewedEvery fact here carries a dated source and the automated checks run on every build. Next scheduled re-check 3 February 2027. No named reviewer has signed it off. It is queued for expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT07711002

A source that has moved or gone is reported by the weekly link check. /audit/

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Connected

Similar pages

cancers

targets

drugs

Sources

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Connected

Similar pages

cancers

targets

drugs

Sources

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Overview

Connected

Similar pages

cancers

targets

drugs

Sources

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Overview

Connected

Similar pages

cancers

targets

drugs

Sources